Title |
Scleroderma-related interstitial lung disease
|
---|---|
Published in |
Respiratory Medicine Case Reports, July 2017
|
DOI | 10.1016/j.rmcr.2017.07.007 |
Pubmed ID | |
Authors |
Sally Suliman, Abdalhamid Al Harash, William Neil Roberts, Rafael L. Perez, Jesse Roman |
Abstract |
Scleroderma-related interstitial lung disease (SSc-ILD) is a pulmonary fibrosing disorder characterized by systemic inflammation and progressive scarring of the lungs that leads to respiratory failure. Although certain immunosuppressive therapies may slow disease progression, current treatment strategies are not curative; consequently, SSc-ILD continues to be a major cause of morbidity and mortality. We present four cases of SSc-ILD that emphasize the importance of early screening and detection, close follow-up, and aggressive management. We also highlight the need for well-conducted clinical trials designed to identify new and effective treatments. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 3 | 60% |
Singapore | 1 | 20% |
Unknown | 1 | 20% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 3 | 60% |
Practitioners (doctors, other healthcare professionals) | 1 | 20% |
Scientists | 1 | 20% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 69 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 11 | 16% |
Other | 10 | 14% |
Researcher | 8 | 12% |
Student > Postgraduate | 7 | 10% |
Student > Master | 6 | 9% |
Other | 5 | 7% |
Unknown | 22 | 32% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 24 | 35% |
Biochemistry, Genetics and Molecular Biology | 4 | 6% |
Agricultural and Biological Sciences | 4 | 6% |
Nursing and Health Professions | 4 | 6% |
Pharmacology, Toxicology and Pharmaceutical Science | 3 | 4% |
Other | 3 | 4% |
Unknown | 27 | 39% |